Research programme: anti-CYP1B1 antibodies - MGI Pharma Biologics
Latest Information Update: 02 Apr 2007
At a glance
- Originator University of Aberdeen; University of Massachusetts Medical School
- Class Antibody diagnostics; Monoclonal antibody diagnostics
- Mechanism of Action Diagnostic imaging enhancers
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Solid tumours
Most Recent Events
- 31 Dec 2004 ZYCOS has been acquired by MGI Pharma and is now called MGI Pharma Biologics
- 16 Jul 2001 Preclinical development for Solid tumours (diagnosis) in USA (unspecified route)